INITIAL COVID-19 TESTING
In September 2020, due to the dire situation at hand, and given the experience Engeenuity had with improving immune responses, we began testing the effect of BioPhoton-X™ technology on SARS-CoV-2, with the Gorgas Institute in Panama. The tests were divided in two, to understand the effect more specifically on the virus. The first test was done to measure the effect of Engeenuity’s Photonic Multiphase Modulators on the SARS-CoV-2 viral load in the supernatant of infected cells, while the second test was measuring the effect of the PMM’s on the ineffectiveness of SARS-CoV-2 in the supernatant of infected cells.
Engeenuity’s Photonic Multiphase Modulators were placed on the outside of petri dishes to treat the vero cells prior to infection with the virus, the first tests were done with 3 exposures for 18 minutes, then 3 exposures for 9 minutes. After mentioned exposure, the vero cells were then inoculated with the virus.
The first test results showed a 50% reduction in viral load and an 84% decrease in effectiveness after 48 hours, while the second test showed a 75% reduction in viral load and a 67.5% decrease in effectiveness. Although the initial results showed positive tendencies, further testing and iterations are necessary to undoubtedly state we have a capacity to aid in the treatment of SARS-CoV-2 and expand our field of treatment to other viruses, improving global health and saving countless lives.
“Engeenuity’s Human Health division is committed to further developing health solutions for an array of diseases and applications.”
– Yossef De Franco, Engeenuity CEO
Further Testing and Research & Development
Decrease in SARS-CoV-2 effectiveness
Decrease in SARS-CoV-2 viral load